Association of cervical spinal cord area changes with atrophy of cortical and subcortical brain regions in clinically isolated syndromes
Author(s): ,
R. Alyafeai
Affiliations:
Multiple Sclerosis Centre of Catalonia & Department of Neuroimmunology, Cemcat-Vall Hebron University Hospital
,
D. Pareto
Affiliations:
Vall Hebron University Hospital-IDI, Magnetic Resonance Unit, Dept. of Radiology, Barcelona, Spain
,
J. Sastre-Garriga
Affiliations:
Multiple Sclerosis Centre of Catalonia & Department of Neuroimmunology, Cemcat-Vall Hebron University Hospital
,
À. Vidal-Jordana
Affiliations:
Multiple Sclerosis Centre of Catalonia & Department of Neuroimmunology, Cemcat-Vall Hebron University Hospital
,
M. Alberich
Affiliations:
Vall Hebron University Hospital-IDI, Magnetic Resonance Unit, Dept. of Radiology, Barcelona, Spain
,
C. Auger
Affiliations:
Vall Hebron University Hospital-IDI, Magnetic Resonance Unit, Dept. of Radiology, Barcelona, Spain
,
M. Tintoré
Affiliations:
Multiple Sclerosis Centre of Catalonia & Department of Neuroimmunology, Cemcat-Vall Hebron University Hospital
,
Á. Rovira
Affiliations:
Vall Hebron University Hospital-IDI, Magnetic Resonance Unit, Dept. of Radiology, Barcelona, Spain
X. Montalban
Affiliations:
Multiple Sclerosis Centre of Catalonia & Department of Neuroimmunology, Cemcat-Vall Hebron University Hospital; Division of Neurology-BartLo MS Centre, St. Michael`s Hospital-University of Toronto, Toronto, ON, Canada
ECTRIMS Online Library. Alyafeai R. Oct 12, 2018; 228965; P1125
Rumaiza Alyafeai
Rumaiza Alyafeai
Contributions
×
Abstract

Abstract: P1125

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - MRI and PET

Introduction: The relationship between spinal cord area and regional atrophy of brain cortical and subcortical structures is not well known, particularly in early MS.
Objective: To investigate (1) the cross-sectional association between spinal cord and regional brain atrophy measures at disease onset, and (2) the relationship between changes in both measures one year after disease onset.
Methods from an ongoing longitudinal clinically isolated syndrome cohort; 3T magnetic resonance imaging (MRI) of the whole brain and upper cervical spinal cord were performed at baseline (within 3 months after the CIS) and at follow-up (12 months). The Upper cervical cross-sectional area (UCCSA) at the level of C2/C3 and measures of both cortical thickness and subcortical volumes were calculated using the semi-automated JIM (v.6) and FreeSurfer(v5.1) software packages respectively on volumetric T1 scans both at baseline and follow-up. For baseline correlations UCCSA and subcortical volumes were normalized by the total intracranial volume. Annualized percentage changes values for UCCSA, cortical thickness and subcortical volumes were calculated by subtraction of baseline and follow-up estimations. The association between spinal cord and brain measures at baseline and their changes after one year was assessed by partial correlations, corrected for both age and gender.
Results: 97 patients were analyzed (56 female / mean age 33.6 years -SD:8.26-) At baseline UCCSA was associated with left insula cortical thickness (r=0.216; P=0.034), and with volumes of the right amygdala (r=0.398; P=0.033), brainstem (r=0.722;P< 0.001), left caudate (r=0.372; P=0.047) and right caudate (r=0.388; P=0.038). A trend for an association was observed in the left cerebellum (r=0.363; P=0.053) and right cerebellum (r=0.352; P=0.061). One-year UCCSA changes were correlated with left cerebellum volume changes (r=0.349; P=0.001), right cerebellum volume changes (r=0.395; P< 0.001), and a trend towards significance was seen for brainstem volume changes (r=0.18; P=0.076).
Conclusions:
Cervical cord atrophy is associated with brain volume loss in several areas, particularly the brainstem and cerebellum. These associations are present even in the early stages of the disease.
Disclosure: RA received a McDonald Fellowship grant from the MSIF.
JS-G has received compensation for participation in advisory boards and speaker bureaus from TEVA, Genzyme, Biogen, Novartis, Roche, Celgene, Merck and Almirall.
CA has received speaking honoraria from Novartis, Stendhal and Biogen.
MA has been sponsored by Novartis Farmacéutica SA Barcelona (Spain).
AVJ receives support for contracts Juan Rodes (JR16/00024) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain; and has received compensation for participation in advisory boards and speaker bureaus from Novartis, Stendhal, Roche and Genzyme-Sanofi
DP has received speaking honoraria from Novartis.
AR serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, SyntheticMR and OLEA Medical, and has received speaker honoraria from Bayer, Genzyme, Sanofi-Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, , Stendhal, Novartis and Biogen Idec.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies